Found: 16
Select item for more details and to access through your institution.
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00758-7
- By:
- Publication type:
- Article
Chronic lymphocytic leukemia treatment algorithm 2022.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00756-9
- By:
- Publication type:
- Article
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00755-w
- By:
- Publication type:
- Article
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00754-x
- By:
- Publication type:
- Article
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00753-y
- By:
- Publication type:
- Article
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00752-z
- By:
- Publication type:
- Article
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00746-x
- By:
- Publication type:
- Article
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00750-1
- By:
- Publication type:
- Article
Breakthrough infections in MPN-COVID vaccinated patients.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00749-8
- By:
- Publication type:
- Article
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00747-w
- By:
- Publication type:
- Article
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00748-9
- By:
- Publication type:
- Article
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00751-0
- By:
- Publication type:
- Article
GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00745-y
- By:
- Publication type:
- Article
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00743-0
- By:
- Publication type:
- Article
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00744-z
- By:
- Publication type:
- Article
Survival trends in hematological malignancies in the Nordic countries through 50 years.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00728-z
- By:
- Publication type:
- Article